Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020
Hospital-acquired pneumonia also called as healthcare associated pneumonia or nosocomial pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital acquired pneumonia is mainly caused due to multidrug resistant microorganisms. The report analyzes the market for late stage candidates for treatment of nosocomial pneumonia, and also provides a detailed review of drugs in early stages of clinical trials. The report studies and estimates market for six late stage along with an elucidation of ten early stage candidates for nosocomial pneumonia treatment.
Hospital-acquired pneumonia also called as healthcare associated pneumonia or nosocomial pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital acquired pneumonia is mainly caused due to multidrug resistant microorganisms. The report analyzes the market for late stage candidates for treatment of nosocomial pneumonia, and also provides a detailed review of drugs in early stages of clinical trials. The report studies and estimates market for six late stage along with an elucidation of ten early stage candidates for nosocomial pneumonia treatment.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong><br />
<strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
4.2.2 Ceftolozane/Tazobactam<br />
4.2.2.1 <strong>Global</strong> Ceftolozane/Tazobactam <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD million)<br />
4.2.3 Ceftazidime/Avibactum<br />
4.2.3.1 <strong>Global</strong> Ceftazidime/Avibactam <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.2.4 Amikacin Inhale<br />
4.2.4.1 <strong>Global</strong> Amikacin Inhale <strong>Market</strong> Revenue, 2016 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.2.5 Plazomicin<br />
4.2.5.1 <strong>Global</strong> Plazomicin <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.2.6 Synflorix Vaccine<br />
4.2.6.1 <strong>Global</strong> Synflorix <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.3 Early Stage (Phase I <strong>and</strong> II)<br />
4.3.1 BAL30072<br />
4.3.2 MEDI4893<br />
4.3.3 AR-301 or KBSA301<br />
4.3.4 AR-101 (or KBPA101) <strong>and</strong> AR-104 (or KBPA104)<br />
4.3.5 AR-201 (or KBRV201)<br />
4.3.6 AR-401 (or KBAB401)<br />
4.3.7 ME1100<br />
4.3.8 GSK 2189242A<br />
4.3.9 V114<br />
Transparency <strong>Market</strong> Research<br />
7
Change language